IL23A and cancer: Thus, in addition to rapamycin treatment, the inhibition of mTORC1 by LAT1 targeting is emerging as a potential therapy for cancer treatment [219], and these therapeutic strategies may be efficient to interfere with an IL-23/IL-1β signaling cascade in inflammatory diseases.